The 7 analysts offering 12-month price forecasts for Rubius Therapeutics Inc have a median target of 19.00, with a high estimate of 40.00 and a low estimate of 3.00. The median estimate represents a +113.00% increase from the last price of 8.92.
The current consensus among 7 polled investment analysts is to Buy stock in Rubius Therapeutics Inc. This rating has held steady since September, when it was unchanged from a Buy rating.Move your mouse over past months for detail
Earnings and Sales Forecasts
Earnings per Share -$0.64
Reporting Date Mar 26
Earnings per Share
Move your mouse over a quarter or year to see how estimates have changed over time.